Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Xuan Wu, Beijing 100053, China.
Evid Based Complement Alternat Med. 2013;2013:896467. doi: 10.1155/2013/896467. Epub 2013 May 8.
We evaluated the effects of the Xuefu Zhuyu capsule (XFZY) and the Shengmai capsule (SM) on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris (UAP) after percutaneous coronary intervention (PCI). Ninety patients with UAP after PCI were randomly and equally assigned to three groups: the XFZY group, the SM group, and the placebo group, with 30 patients in each group. Six syndrome factors (including Qi deficiency, yin deficiency, yang deficiency, blood stasis, phlegm, and Qi stagnation) and 4 inflammatory markers (high-sensitivity C-reactive protein (Hs-CRP), endothelins-1 (ET-1), matrix metalloproteinases-9 (MMP-9), and homocysteine (Hcy)) were observed at week 0 and at the 1st, 4th and 12th weeks. In conclusion, the evolution of syndromes present in patients with UAP after PCI followed these trends (1) The deficiency syndromes gradually increased during a 12-week period, but the excess syndromes first gradually decreased and then mildly increased after PCI. (2) XFZY and SM can prevent excess syndromes from increasing in the later stages and prevent deficiency syndromes from increasing in all stages. (3) XFZY and SMcan reduce the levels of the inflammatory markers, especially in the later stages after PCI.
我们评估了血府逐瘀胶囊（XFZY）和生脉胶囊（SM）对经皮冠状动脉介入治疗（PCI）后不稳定型心绞痛（UAP）患者证候演变和炎症标志物的影响。90 例 PCI 后 UAP 患者随机等分为三组：XFZY 组、SM 组和安慰剂组，每组 30 例。观察 6 个证候因素（包括气虚、阴虚、阳虚、血瘀、痰浊和气滞）和 4 个炎症标志物（高敏 C 反应蛋白（Hs-CRP）、内皮素-1（ET-1）、基质金属蛋白酶-9（MMP-9）和同型半胱氨酸（Hcy））在 0 周和第 1、4、12 周。总之，PCI 后 UAP 患者的证候演变呈现以下趋势：（1）虚证在 12 周内逐渐增加，但实证先逐渐减少，然后 PCI 后轻度增加。（2）XFZY 和 SM 可预防后期过度证候的增加，预防各期虚证的增加。（3）XFZY 和 SM 可降低炎症标志物的水平，尤其是 PCI 后晚期。
